AI Article Synopsis
- Non-infectious choroiditis includes immune-mediated diseases categorized into two groups: diseases affecting the choriocapillaris and diseases involving the choroidal stroma.
- The study aims to clarify the underlying mechanisms of these diseases and suggest appropriate immunomodulatory therapies based on literature and clinical data.
- It emphasizes the necessity for aggressive and long-term immunosuppressive treatment for managing various types of immune-mediated choroiditis.
Article Abstract
Non-infectious choroiditis comprises immune-mediated diseases resulting from diverse pathophysiological mechanisms. These conditions are sub-divided into two main groups, (1) diseases of the choriocapillaris and (2) diseases of the choroidal stroma. The purpose of this study is to expose the pathophysiology of the most common diseases of both these groups and recommend the optimal immunomodulatory/immunosuppressive therapy of each analyzed condition based on literature data and data from our own centers. Material and Methods: Narrative review. In the group of choriocapillaritis entities or primary inflammatory choriocapillaropathies (PICCPs) including multiple evanescent white dot syndrome (MEWDS), acute posterior multifocal placoid pigment epitheliopathy (APMPPE), idiopathic multifocal choroiditis (MFC) and serpiginous choroiditis (SC), as well as secondary choriocapillaritides including acute syphilitic posterior multifocal placoid chorioretinitis (ASPMPC) and tuberculosis-related SC (TB-SC), were analyzed. In the group of stromal choroidites, HLA-A29 birdshot retinochoroiditis (BRC) and Vogt-Koyanagi-Harada (VKH) disease were included. For each entity a literature search, in the PubMed database, on treatment was performed and analyzed and the therapeutic attitudes of our own centers were presented. Management of immune-mediated choroiditis implies vigorous immunosuppressive therapy given in a prompt and prolonged fashion in most of these entities.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031533 | PMC |
| http://dx.doi.org/10.3390/ph15040398 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment with oclacitinib, a Janus kinase inhibitor, down-regulates and up-regulates CD25 and Foxp3 expression, respectively, in peripheral blood T cells of dogs with atopic dermatitis.
BMC Vet Res
October 2024
Department of Animal Reproduction with Clinic, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Oczapowskiego 14, 10-719, Olsztyn, Poland.
Article Synopsis
- Oclacitinib (OCL) is a Janus kinase inhibitor approved for treating atopic dermatitis (AD) in dogs, and this study aimed to evaluate its effects on T cell populations and safety in affected dogs.
- After 28 days of treatment with OCL, certain T cell counts (CD4 and CD8) showed no significant changes compared to baseline, although an increase was noted on day 7, followed by a decrease in specific subsets on days 14 and 28.
- The study concluded that OCL treatment appears safe regarding T cell counts and suggests its therapeutic benefits may come from lowering eosinophil levels and reducing CD25 expression on CD4 Teff cells linked to AD.
Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions.
Am J Hematol
December 2024
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Article Synopsis
- - The neonatal Fc receptor (FcRn) plays a key role in transporting and protecting IgG antibodies, and researchers are exploring the potential of FcRn inhibitors to treat various immune-related diseases.
- - Studies indicate that FcRn inhibitors can effectively lower total IgG levels without affecting its production or the levels of other antibody types, showing promise as a safer alternative to existing immunosuppressive therapies.
- - More extensive clinical trials with diverse patient groups are needed to confirm the effectiveness and safety of FcRn inhibitors before they can become standard treatment options for hematologic conditions related to IgG antibodies.
Frequency of Topical Immunomodulatory and Immunosuppressive Therapies for Ocular Chronic Graft-versus-Host Disease.
J Clin Med
August 2024
Department of Ophthalmology, Charité-University Medicine Berlin, Corporate Member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353 Berlin, Germany.
The purpose of the study was to evaluate the frequency of topical immunomodulatory and immunosuppressive therapies in patients with ocular chronic graft-versus-host disease (cGVHD) in consideration of inflammatory activity and systemic immunosuppressive therapies in a tertiary care university hospital setting. We included 95 adult patients (48 male, 47 female) with ocular chronic graft-versus-host disease (cGVHD) after alloHSCT (median age 49.5 years).
View Article and Find Full Text PDFHigh mobility group box 1 (HMGB1) is a potential disease biomarker in cell and mouse models of Duchenne muscular dystrophy.
Biol Open
September 2024
Division of Pediatric Pathology, Department of Pathology and Laboratory Medicine and Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disorder affecting 1:3500 male births and is associated with myofiber degeneration, regeneration, and inflammation. Glucocorticoid treatments have been the standard of care due to immunomodulatory/immunosuppressive properties but novel genetic approaches, including exon skipping and gene replacement therapy, are currently being developed. The identification of additional biomarkers to assess DMD-related inflammatory responses and the potential efficacy of these therapeutic approaches are thus of critical importance.
View Article and Find Full Text PDFCurrent pharmacological solutions for Behçet's syndrome.
Expert Opin Pharmacother
February 2023
Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Introduction: Behçet's syndrome (BS) has a heterogeneous clinical phenotype, and its clinical manifestations may respond differently to drugs commonly used to treat BS. The type, dose, and duration of immunomodulatory, immunosuppressive, and biologic agents should be tailored individually.
Areas Covered: We reviewed the literature for articles on BS management that were published until June 2022 and summarized the management options in BS for each type of organ involvement.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!